权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Human-scale microfluidic artificial lung

人体规模微流控人工肺

基本信息

批准号：
10355523
负责人：
Joseph Allen Potkay
金额：
$ 69.19万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-15 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10355523
关键词：
Acute Acute Respiratory Distress Syndrome Adult Adverse effects Affect Air American Animals Anticoagulation Area Automation Biomimetics Blood Blood Platelets Blood flow Carbon Dioxide Cattle Cause of Death Cells Cessation of life Chronic Chronic Obstructive Pulmonary Disease Chronic lung disease Coagulation Process Collaborations Custom Development Device Designs Devices Diffusion Disabled Persons Engineering Evolution Excision Exhibits Experimental Designs Film Foreign Bodies Future Gases Goals Human In Vitro Industrialization Investigation Laboratories Lasers Liquid substance Lung Lung diseases Membrane Methods Microfluidic Microchips Microfluidics Modification Nitric Oxide Patients Performance Physiological Plasma Polyurethanes Positioning Attribute Procedures Rehabilitation therapy Research Proposals Resistance Specialist Structure Surface System Techniques Technology Testing Theoretical model Thinness Time United States artificial lung biomaterial compatibility blood pump clinical application design experience first-in-human fluorescence imaging hemocompatibility hydrophilicity improved innovation mortality novel operation portability pressure pulmonary rehabilitation respiratory response seal shear stress sheep model surface coating technology development

项目摘要

The long-term goal of this technology development project is to improve rehabilitation from lung disease through the development of the first truly portable, biocompatible, artificial lung capable of short and long term respiratory support. Current artificial lungs have recently been used to rehabilitate lung disease patients; however, significant advances in gas exchange, biocompatibility, and portability are required to fully realize their potential. Microfluidic artificial lungs promise to enable a new class of truly portable artificial lungs through feature sizes and blood channel designs that closely mimic those found in their natural counterpart. The objectives of the current R01 proposal, which seeks to propel our microfluidic artificial lung toward initial human applications, are to: 1) develop a roll-to-roll manufacturing system capable of producing the first human-scale microfluidic artificial lungs; 2) optimize the performance and biocompatibility of human-scale microfluidic artificial lungs; and, 3) test a human-scale microfluidic artificial lung in acute and chronic animal studies. These objectives are critical to advancing this promising technology toward initial acute systems for pulmonary rehabilitation.

这项技术开发项目的长期目标是改善肺部疾病的康复通过开发第一个真正便携的、生物相容的、能够短期和长期使用的人工肺，呼吸支持目前的人工肺最近已被用于肺病患者的康复; 然而，要完全实现这一目标，还需要在气体交换、生物相容性和便携性方面取得重大进展他们的潜力微流体人工肺有望通过以下方式实现新型的真正便携式人工肺：特征尺寸和血液通道设计与天然对应物中的相似。的目前R 01提案的目标，旨在推动我们的微流体人工肺向最初的人类应用，是：1）开发一个卷到卷的制造系统，能够生产第一个人类规模的微流控人工肺; 2）优化人规模微流控人工肺的性能和生物相容性人工肺;以及3）在急性和慢性动物研究中测试人类规模的微流体人工肺。这些目标是至关重要的，以推进这一有前途的技术对初始急性系统的肺康复活动.